Get the Daily Brief
Latest Biotech News
Atlas Venture Raises $400 Million 'Opportunity Fund' to Support Existing Biotech Startups
Atlas Venture has announced the closing of a $400 million Opportunity Fund III, aimed at providing follow-up financing to biotechs in its existing portfolio. This fund targets promising companies...
Treeline Biosciences Emerges with $1.1 Billion Raised and Three Cancer Programs in Clinic
After years under the radar, Treeline Biosciences disclosed its first clinical candidates targeting various cancers and announced a $200 million extension of its Series A funding, lifting total...
FDA Implements New Pathway for Ultra-Rare Disease Drug Approvals
The U.S. Food and Drug Administration unveiled the Rare Disease Evidence Principles (RDEP), a coordinated review program between its drug and biologics centers to facilitate expedited approval of...
FDA Commits to Publishing Complete Drug Rejection Letters to Enhance Transparency
FDA Commissioner Marty Makary announced a new policy to publicly release redacted complete response letters (CRLs) simultaneously with drug sponsors receiving them. This landmark decision aims to...
Charm Therapeutics Secures $80 Million to Advance Menin Inhibitor for Leukemia
London-based Charm Therapeutics completed an $80 million Series B funding round led by New Enterprise Associates and DR One to develop its next-generation menin inhibitor targeting acute myeloid...
Novel High-Throughput Antibody Platform Accelerates Therapeutic Discovery
Scientists at the University of Illinois Urbana-Champaign revealed oPool+ display, a high-throughput technology capable of synthesizing and assessing hundreds of antibodies in parallel against...
Amgen Invests Over $600 Million in U.S. Center for Science and Innovation
Amgen announced a $600 million investment to establish a state-of-the-art scientific research and development center at their global headquarters in Thousand Oaks, California. The facility aims to...
Novartis and Argo Biopharma Expand $9 Billion Collaboration on RNAi Therapeutics
Novartis has deepened its partnership with Shanghai-based Argo Biopharma, signing a new deal valued at up to $5.2 billion, including $160 million upfront payments and substantial milestones. This...
Medical Community Criticizes Florida's Plan to End Vaccine Mandates
Florida's decision to remove all vaccine mandates has drawn sharp criticism from healthcare experts and organizations who warn it threatens public health by increasing the risk of preventable...
Charm Therapeutics Raises $80 Million to Advance Menin Inhibitor for Leukemia
London-based Charm Therapeutics secured $80 million in a Series B funding round co-led by New Enterprise Associates and DR One, aimed at advancing its menin inhibitor drug candidate targeting...
Atlas Venture Closes $400 Million Opportunity Fund to Support Biotech Portfolio
Atlas Venture announced the close of a $400 million Opportunity Fund III to support follow-on investments in its existing portfolio of biotech startups. The fund aims to provide additional capital...
FDA Unveils New Review Pathway for Ultra-Rare Disease Therapies
The Food and Drug Administration introduced the Rare Disease Evidence Principles (RDEP) program to offer a more flexible and coordinated review process for drugs targeting ultra-rare genetic...
Treeline Biosciences Reveals Clinical Candidates, Raises $200 Million Extension
After years of secrecy, Treeline Biosciences disclosed its first three clinical-stage oncology drug candidates, including a protein degrader targeting BCL6 in lymphoma, a KRAS inhibitor with broad...
AI-Powered High-Throughput Platform Accelerates Antibody Discovery
Researchers at the University of Illinois Urbana-Champaign developed oPool+ display, a high-throughput antibody synthesis and specificity characterization platform that can generate and screen...
Wave Life Sciences Updates RNA Editing Therapy Data for Alpha-1 Antitrypsin Deficiency
Wave Life Sciences reported data from ongoing phase Ib/IIa trials of its RNA editing oligonucleotide, WVE-006, for alpha-1 antitrypsin deficiency (AATD). The therapy demonstrated durable increases...
FDA Commissioner Moves to Publish Drug Rejection Letters to Enhance Transparency
Amid ongoing efforts to increase regulatory transparency, FDA Commissioner Marty Makary announced plans to publicly release complete response letters (CRLs) for drug applications at the time they...
Novartis and Arrowhead Sign $200 Million Deal to Develop RNAi Therapy for Parkinson’s Disease
Novartis entered a global collaboration with Arrowhead Pharmaceuticals, investing $200 million upfront to develop ARO-SNCA, an siRNA-based therapy targeting alpha-synuclein for synucleinopathies...
FDA Introduces Single-Arm Trial Acceptability for Ultra-Rare Disease Drug Approvals
Building on previous rare disease guidance, the FDA unveiled the Rare Disease Evidence Principles (RDEP), facilitating streamlined approval for therapies treating ultra-rare conditions affecting...
Targeting Diseased Cells with Engineered Protein Crunch: A New Therapeutic Pathway
Kyoto University researchers have engineered a synthetic protein, named Crunch, that reprograms innate immune phagocytic cells to selectively engulf and remove diseased living cells. This...
Sucralose Consumption Linked to Blunted Cancer Immunotherapy Response
New research from the University of Pittsburgh reveals that sucralose, a common artificial sweetener, disrupts the efficacy of cancer immunotherapies by altering the gut microbiome. The team...